0J9P Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Incyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.38 |
| 52 Week High | US$83.54 |
| 52 Week Low | US$50.02 |
| Beta | 0.76 |
| 1 Month Change | 1.15% |
| 3 Month Change | -1.12% |
| 1 Year Change | 17.21% |
| 3 Year Change | -8.20% |
| 5 Year Change | -4.00% |
| Change since IPO | -28.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0J9P | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.1% | -2.3% | -2.2% |
| 1Y | 17.2% | -11.7% | 6.8% |
Return vs Industry: 0J9P exceeded the UK Biotechs industry which returned -11.7% over the past year.
Return vs Market: 0J9P exceeded the UK Market which returned 6.8% over the past year.
Price Volatility
| 0J9P volatility | |
|---|---|
| 0J9P Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0J9P has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0J9P's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,617 | Herve Hoppenot | www.incyte.com |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive.
Incyte Corporation Fundamentals Summary
| 0J9P fundamental statistics | |
|---|---|
| Market cap | US$13.11b |
| Earnings (TTM) | US$32.62m |
| Revenue (TTM) | US$4.24b |
401.8x
P/E Ratio3.1x
P/S RatioIs 0J9P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0J9P income statement (TTM) | |
|---|---|
| Revenue | US$4.24b |
| Cost of Revenue | US$2.76b |
| Gross Profit | US$1.48b |
| Other Expenses | US$1.45b |
| Earnings | US$32.62m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 35.00% |
| Net Profit Margin | 0.77% |
| Debt/Equity Ratio | 0% |
How did 0J9P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 00:58 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Incyte Corporation is covered by 51 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Thomas Russo | Baird |
| Ishan Majumdar | Baptista Research |